Pashtoon Kasi, Medical Director of GI Medical Oncology at City of Hope Orange County, shared on LinkedIn:
“What NEST taught us.
Lesson 4: Toxicity management.
Our gastroenterology colleagues managing inflammatory bowel diseases have moved on to steroid-sparing drugs. We in oncology need to learn from them.
Early use decreases severity and need for steroids.”
Title: Neoadjuvant Botensilimab/Balstilimab for localized mismatch repair proficient and deficient colon cancer: Results of the NEST phase 2 clinical trial
Authors: Manish A. Shah, Erika Hissong, Mehraneh D. Jafari, Pashtoon Murtaza Kasi, Maider Astorkia, Sahrish Khan, Casey Owens, Zhengming Chen, Heather Yeo, Fabio Socciarelli, Sandipto Sarkar, Alana Nguyen, Despina Siolas, Allyson Ocean, Kelly Garrett, Lea Lowenfeld, Alessio Pigazzi, Preethi Guniganti, Sanjay Patel, Doron Betel, Manuel Hidalgo
You can also read:
Stefanie Perna Nacar: Botensilimab/Balstilimab Shows Major Pathologic Responses in Colon Cancer
